Clinical Trial Update: Study of the Xience V Everolimus-eluting Stent in Saphenous Vein Graft Lesions [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the Xience V everolimus-eluting stent in saphenous vein graft lesions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Coronary Artery Disease

Drugs mentioned

• Xience V Everolimus-eluting Stent (everolimus-eluting stent)

Snippet

Sponsor: North Texas Veterans Healthcare System | Conditions: Coronary Artery Bypass, Atherosclerosis | Phase 4 | Status: COMPLETED